JACOB MANDEL to Treatment Outcome
This is a "connection" page, showing publications JACOB MANDEL has written about Treatment Outcome.
Connection Strength
0.111
-
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
Score: 0.046
-
Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364.
Score: 0.013
-
Newly Diagnosed Optic Pathway Glioma During Pregnancy. World Neurosurg. 2019 Jul; 127:58-62.
Score: 0.012
-
Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol. 2017 Oct; 135(1):75-81.
Score: 0.011
-
Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.
Score: 0.010
-
Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol. 2015 Sep; 124(3):501-6.
Score: 0.010
-
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
Score: 0.009